Pharma

Your Article Summary

See Latest Articles

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Repligen, 06/12/09

Repligen Corporation reported results for the fourth quarter and fiscal year 2009, ended March 2009. Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008 ended March 2008, an increase of $10,066,000 or 52%. Total revenue for the year was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the year was $14,529,000 and royalty and other revenue was $14,833,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia and grant revenue from the Muscular Dystrophy Association.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Ultrasound, nuc med on the upswing
Canadian Healthcare Technology, 10/16/09

Explaining Innovation
PharmExec, 10/16/09

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

See All of Financial Reports